Literature DB >> 20709569

A randomized, controlled trial on dexmedetomidine for providing adequate sedation and hemodynamic control for awake, diagnostic transesophageal echocardiography.

Lebron Cooper1, Keith Candiotti, Christopher Gallagher, Ernesto Grenier, Kristopher L Arheart, Michael E Barron.   

Abstract

OBJECTIVE: Transesophageal echocardiography (TEE) has become established as a sensitive and accurate diagnostic method for the rapid assessment of myocardial function. It was theorized that dexmedetomidine (Precedex; Hospira, Inc, Lake Forest, IL) might prove to be useful for sedating patients while undergoing TEE.
DESIGN: A prospective, randomized trial was designed comparing dexmedetomidine versus standard therapy (eg, midazolam and opioids) for sedation.
SETTING: This trial was performed in a tertiary care, single-institution university hospital. PARTICIPANTS: Males and females, American Society of Anesthesiologists I to IV, ages 18 to 65 years, requiring diagnostic TEE. Patients were excluded if pregnant, if they had taken benzodiazepines or opioids within 24 hours, or if they were deemed to be too unstable to receive any kind of sedation.
INTERVENTIONS: Patients were randomized to standard therapy or dexmedetomidine infusion groups. Sedation was assessed at 6 time points. Pulse oximetry, electrocardiogram, heart rate, noninvasive blood pressure, and respiratory rate were monitored. Additional variables measured were the amount of each drug given, the time of the TEE procedure, and the time to recovery.
MEASUREMENTS AND MAIN RESULTS: A survey about the quality of sedation, the level of comfort, and whether or not they would accept this type of sedation again was administered after recovery from sedation. Demographic data and patient questionnaire responses were reported as means and standard errors or percents and were analyzed with the t test and chi-square test. Twenty-two patients were enrolled. Hemodynamics were statistically different between the two groups at several time points. Both systolic and diastolic blood pressures (BP) were elevated in the standard therapy group, whereas the dexmedetomidine group had a lower BP. Heart rate was elevated significantly in the standard therapy group compared with the dexmedetomidine group. There was no statistical or clinical difference between the groups in terms of oxygenation or respiratory rate.
CONCLUSIONS: The authors concluded that dexmedetomidine appears equivalent in achieving adequate levels of sedation without increasing the rate of respiratory depression or decreasing oxygen saturation compared with standard therapy, and it may be better in achieving desired hemodynamic results.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709569     DOI: 10.1053/j.jvca.2010.06.006

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  19 in total

Review 1.  Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  Dexmedetomidine in current anaesthesia practice- a review.

Authors:  Shagufta Naaz; Erum Ozair
Journal:  J Clin Diagn Res       Date:  2014-10-20

3.  Anesthesia Practice in Pediatric Radiation Oncology: Mayo Clinic Arizona's Experience 2014-2016.

Authors:  Narjeet Khurmi; Perene Patel; Sarang Koushik; Thomas Daniels; Molly Kraus
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 4.  Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers.

Authors:  Narjeet Khurmi; Perene Patel; Molly Kraus; Terrence Trentman
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

5.  Dexmedetomidine inhibits tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide-stimulated astrocytes by suppression of c-Jun N-terminal kinases.

Authors:  Xiaobao Zhang; Jun Wang; Wenyi Qian; Jingjing Zhao; Li Sun; Yanning Qian; Hang Xiao
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

6.  Clinical use of dexmedetomidine in monitored anesthesia care.

Authors:  Soo Kyung Lee
Journal:  Korean J Anesthesiol       Date:  2011-12-20

7.  Adequate sedation with single-dose dexmedetomidine in patients undergoing transurethral resection of the prostate with spinal anaesthesia: a dose-response study by age group.

Authors:  Jeongmin Kim; Won Oak Kim; Hye-Bin Kim; Hae Keum Kil
Journal:  BMC Anesthesiol       Date:  2015-01-27       Impact factor: 2.217

8.  Optimal effect-site concentration of remifentanil when combined with dexmedetomidine in patients undergoing cystoscopy.

Authors:  Bongha Heo; Minsun Kim; Hyunjung Lee; Sanghee Park; Seongwook Jeong
Journal:  Korean J Anesthesiol       Date:  2014-01-28

9.  Dexmedetomidine may benefit cognitive function after laparoscopic cholecystectomy in elderly patients.

Authors:  Jingjun Chen; Junqiang Yan; Xueping Han
Journal:  Exp Ther Med       Date:  2012-11-13       Impact factor: 2.447

10.  Dexmedetomidine sedation for transesophageal echocardiography during percutaneous atrial septal defect closure in adult.

Authors:  Jae Wook Jung; Gwang Cheol Go; Sang Yoon Jeon; Sira Bang; Ki Hwa Lee; Yong Han Kim; Dong-Kie Kim
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.